博安生物(06955)绩后跌超8%，截至发稿，跌7.06%，报14.61港元，成交额9830.77万港元。 消息面上，博安生物发布中期业绩，上半年收入人民币3.93亿元，同比增加8.4%；毛利为人民币2.83亿 元，同比基本持平；母公司拥有人应占溢利为人民币2051.4万元，同比减少66.7%。期内收入增加主要 是由于产品(博优诺、博优倍及博洛加)销售较截至2024年6月30日止六个月持续增长15.9%至人民币3.853 亿元。 值得注意的是，8月9日，博安生物宣布，其自主研发的博优平(度拉糖肽注射液)已获得国家药品监督管 理局的上市批准，用于成人2型糖尿病患者的血糖控制。该产品是全球首个且当前唯一获批上市的度易 达(英文商品名：Trulicity)的生物类似药，国内尚无其他国产度拉糖肽注射液进入上市许可申请阶段。 博优平在中国大陆的商业化由博安生物与上药控股有限公司(上药控股)合作开展。 ...

Core Insights - The company Boan Biotech has received approval from the National Medical Products Administration for its self-developed drug, Boyouping (Dulaglutide Injection), aimed at blood sugar control in adult patients with type 2 diabetes [1] - Boyouping is a long-acting GLP-1 receptor agonist, and its commercialization in mainland China will be conducted in collaboration with Shanghai Pharmaceuticals [1] Distribution and Marketing - Shanghai Pharmaceuticals has a comprehensive distribution network covering 25 provinces and over 70,000 medical institutions, supported by nearly 1,000 professional marketing personnel [1] - The company will leverage its integrated marketing services and extensive market coverage to accelerate the distribution of Boyouping across hospitals, retail pharmacies, and DTP specialty pharmacies nationwide [1] Company Overview - Boan Biotech operates with an integrated "R&D-production-sales" model and is a local biopharmaceutical company [1] - The company has developed innovative antibody drugs based on three technology platforms: antibody-drug conjugate technology, bispecific T-cell engager technology, and fully human antibody transgenic mice and phage display technology [1] - In the biosimilar drug sector, the company has successfully launched four products [1] Financial Performance - For the year 2024, the company is projected to achieve a revenue of 730 million yuan, representing a year-on-year growth of 17.5% [1] - The net profit is expected to be 73.19 million yuan, marking a turnaround from previous losses [1]